Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.06%
#3 CoW Protocol CoW Protocol +41.78%
#4 Glidr Glidr +36.87%
#5 Humanity Humanity +26.87%
#6 Codatta Codatta +21.56%
#7 Walrus Walrus +20.27%
#8 Enso Enso +18.27%
#9 The Black Bull The Black Bull +16.62%
#10 Tutorial Tutorial +14.28%
Coin of the day
EXOD EXOD
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
CASI Pharmaceuticals, Inc. CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc.

CASI
Classement en actions #36784
CASI Pharmaceuticals, Inc. is a biopharmaceutical firm focused on the... CASI Pharmaceuticals, Inc. is a biopharmaceutical firm focused on the development and market introduction of medical treatments and drugs across China, the United States, and globally. Its marketed product, EVOMELA, is an intravenous formulation of melphalan, utilized for conditioning prior to stem cell transplantation and as a palliative option for patients suffering from multiple myeloma. The company's developmental pipeline encompasses several experimental therapies. This includes CNCT19, an investigational autologous CD19 CAR-T therapy aimed at treating patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). BI-1206 is currently in Phase I/II trials, combined with the anti-PD1 therapy Keytruda, for solid tumors, and is also undergoing a Phase I/IIa study in conjunction with MabThera (rituximab) for individuals with relapsed/refractory NHL. CB-5339 is advancing through Phase I clinical trials for acute myeloid leukemia and myelodysplastic syndrome. Further additions to its pipeline are CID-103, targeting multiple myeloma patients, and Thiotepa, which possesses a broad range of indications, including its use as a conditioning therapy for various allogeneic hematopoietic stem cell transplants. Additionally, long-acting injectable formulations of Octreotide are being developed for managing acromegaly and alleviating symptoms associated with different neuroendocrine tumors. CASI maintains licensing agreements with Juventas Cell Therapy Ltd, BioInvent International AB, Black Belt Therapeutics Limited, and Cleave Therapeutics, Inc. It has also forged distribution partnerships with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd, Pharmathen Global BV, and Riemser Pharma GmbH. Incorporated in 1991, this Rockville, Maryland-based company was formerly known as EntreMed, Inc. before adopting its current name, CASI Pharmaceuticals, Inc., in June 2014.
Prix de l'action
$0.15
Dernière synchronisation: 2026-04-13
Capitalisation boursière
$2.33M
Changement (1 jour)
3.88%
Changement (1 an)
-93.70%
Pays
CN
Échange CASI Pharmaceuticals, Inc. (CASI)

Catégorie

Healthcare
Historique du prix de l'action pour CASI Pharmaceuticals, Inc. (CASI)
Prix de clôture le plus élevé : $0.14 le 2026-04-01

Prix de clôture le plus bas : $1.67K le 1996-06-01
Historique du prix de l'action de CASI Pharmaceuticals, Inc. de 1996 à 2026
Performance annuelle du prix de l'action
Année Performance
2026 (TTM) 32.52%
2025 -72.44%
2024 -53.46%
2023 283.37%
2022 -79.05%
2021 -68.42%
2020 -16.54%
2019 -24.32%
2018 30.06%
2017 155.84%
2016 26.21%
2015 -27.36%
2014 -14.44%
2013 12.11%
2012 11.08%
2011 -77.05%
2010 -43.19%
2009 302.44%
2008 -82.88%
2007 -24.57%
2006 -17.29%
2005 -25.64%
2004 -20.23%
2003 227.92%
2002 -87.78%
2001 -56.55%
2000 -23.06%
1999 11.82%
1998 101.68%
1997 -19.22%
1996 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $505.24 28.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $846.09 29.41%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $731.69 6.47%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.07K -6.40%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $251.82 11.75%
BE